Physician profile
Michael G Orr
NPI 1144264136
$25,869.05
in general payments reported to CMS, 2019-2025
23 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $6,284 · 2021: $16K · 2022: $557 · 2023: $1,016 · 2024: $1,059 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $510 · Consulting Fee: $500 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $510.00 |
| Consulting Fee | $500.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $22,305.44 | 2019-2024 | Lensar Laser System |
| Glaukos Corporation | $1,421.32 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Radius |
| Allergan, INC. | $359.89 | 2019-2021 | |
| Alcon Vision LLC | $295.75 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Rxsight INC | $288.87 | 2020-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Abbvie INC. | $276.61 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $170.68 | 2021-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $157.30 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $140.97 | 2023-2024 | Envista Mx60 Iol, Xiidra, Miebo |
| Mallinckrodt Hospital Products INC. | $87.83 | 2025 | Acthar |
| Dompe US, INC. | $64.07 | 2025 | Oxervate |
| Ocular Therapeutix, INC. | $58.03 | 2021-2025 | Dextenza |
| Biotissue Holdings INC. | $45.87 | 2021-2025 | |
| Notal Vision, INC. | $30.56 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $25.26 | 2025 | Xdemvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $22.81 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.47 | 2019 | |
| Sight Sciences, INC. | $20.95 | 2021 | |
| Shire North American Group INC | $20.45 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $19.30 | 2022 | |
| Z-Medica, LLC | $14.65 | 2019 | |
| Sun Pharmaceutical Industries INC. | $13.95 | 2023 | Cequa |
| New World Medical,INC. | $6.02 | 2022-2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.